Introduction {#hiv12505-sec-0005}
============

Canada and the UK are two high‐income countries with notable differences in health care provision for people living with HIV (PLWH). However, whether clinical prognoses differ for PLWH receiving care between these two settings remains undefined.

Ongoing health care and treatment for all 107 800 PLWH in the UK is provided free of charge through the National Health Service (NHS) [1](#hiv12505-bib-0001){ref-type="ref"}. HIV treatment guidelines and standards of care documents published by the British HIV Association (BHIVA), together with a national service specification from NHS England, provide a universal national benchmark to guide clinical HIV care and prescribing decisions throughout the UK [2](#hiv12505-bib-0002){ref-type="ref"}, [3](#hiv12505-bib-0003){ref-type="ref"}.

In Canada, there are 75 500 PLWH [4](#hiv12505-bib-0004){ref-type="ref"}, and although select provinces provide treatment guidelines, no acknowledged national standards in HIV care exist. In British Columbia (BC) and Québec, HIV treatment is formally standardized by comprehensive provincial guidelines [5](#hiv12505-bib-0005){ref-type="ref"}, [6](#hiv12505-bib-0006){ref-type="ref"}. Other Canadian provinces informally follow International Antiviral Society (IAS) guidelines [7](#hiv12505-bib-0007){ref-type="ref"} and/or recommendations from the US Department of Health and Human Services [8](#hiv12505-bib-0008){ref-type="ref"}. Antiretroviral therapy (ART) funding mechanisms vary across Canada, ranging from complete coverage to partial coverage or income‐based reimbursement [9](#hiv12505-bib-0009){ref-type="ref"}, [10](#hiv12505-bib-0010){ref-type="ref"}, [11](#hiv12505-bib-0011){ref-type="ref"}.

Recent work has shown reduced attrition at all stages of the HIV care cascade among PLWH in the UK compared with Canadian settings [12](#hiv12505-bib-0012){ref-type="ref"}. In light of the aforementioned differences in HIV care provision between the UK and Canada, and emerging disparities in the HIV care cascade [12](#hiv12505-bib-0012){ref-type="ref"}, we sought to compare all‐cause mortality within a subset of the populations infected with HIV via sexual transmission in these two settings. All‐cause mortality has been recognized as a preferred prognostic indicator for PLWH [13](#hiv12505-bib-0013){ref-type="ref"}. This outcome variable was selected as a basic, easily interpreted measure of cohort health status [13](#hiv12505-bib-0013){ref-type="ref"}.

Methods {#hiv12505-sec-0006}
=======

Subsets of data from two national cohort collaborations investigating HIV clinical outcomes and treatment responses, the Canadian Observational Cohort (CANOC) collaboration and UK Collaborative HIV Cohort (CHIC) study, were merged in September 2014. At this time, data were available from 1 January 2000 up to the end of 2012 for both cohort collaborations.

CANOC collaboration {#hiv12505-sec-0007}
-------------------

The CANOC collaboration is a multi‐site cohort of PLWH initiating ART for the first time after 1 January 2000, and was established to evaluate patterns of treatment uptake and response, and health service provision and outcomes across Canada. Participants must reside in Canada and be aged at least 18 years, with documented HIV infection. Each contributing cohort site performs data extraction of demographic, laboratory and clinical variables, submitted annually to the coordinating centre in Vancouver for data merging, cleaning and analysis. At the time of writing, almost 10 000 participants had contributed data from eight cohorts located within the country\'s most populous provinces: BC, Ontario and Québec. The BC cohort submits full population‐level data, whereas sites in Ontario and Québec largely capture clinic‐based data. Ethics board approval of the CANOC collaboration was granted to each participating cohort site. A detailed cohort profile has been published [14](#hiv12505-bib-0014){ref-type="ref"}.

UK CHIC study {#hiv12505-sec-0008}
-------------

The UK CHIC study is a collaboration that currently includes 19 participating NHS HIV treatment centres. The study was established in 2001 with the aim of evaluating treatment uptake and clinical outcomes of PLWH accessing care in the UK [15](#hiv12505-bib-0015){ref-type="ref"}, [16](#hiv12505-bib-0016){ref-type="ref"}. The UK CHIC study currently includes over 50 000 participants aged \> 16 years, who have received HIV care at one of the collaborating centres in England and Scotland on at least one occasion since 1996. Each participating centre submits electronic data annually to the coordinating group based at University College London (UCL) and the Medical Research Council Clinical Trials Unit. The coordinating group merges de‐identified data into a final data set after performing data cleaning and quality checks. The UK CHIC study has been approved by a multi‐centre research ethics committee and by local ethics committees. Further details can be found in the cohort profile [16](#hiv12505-bib-0016){ref-type="ref"}.

Inclusion criteria {#hiv12505-sec-0009}
------------------

Participants included in this merged collaborative analysis were aged 18 years or older, initiated ART for the first time between 2000 and 2012, had complete information on gender, sexual transmission risk, CD4 cell count and HIV viral load (VL) prior to ART initiation (baseline), and had at least one follow‐up measure of CD4 cell count and VL. Participant inclusion was limited to individuals presumed infected via sexual routes to improve cohort comparability, as a consequence of the low prevalence of individuals who have acquired HIV through injecting drug use (IDU) in the UK compared with Canada (2 *vs*. 17%, respectively) [1](#hiv12505-bib-0001){ref-type="ref"}, [17](#hiv12505-bib-0017){ref-type="ref"}. Nonetheless, we carried out a sensitivity analysis including persons with a history of IDU to evaluate potential bias that may have been introduced as a result of their exclusion from the primary analysis.

Measures {#hiv12505-sec-0010}
--------

### Primary outcome variable {#hiv12505-sec-0011}

The primary outcome of interest was all‐cause mortality, defined as date of death. In the UK CHIC study, date of death is requested as part of the annual data submission from participating centres. Additionally, records for the majority (94%) of UK CHIC participants are linked to National HIV Surveillance data at Public Health England to supplement information on deaths. These data sets also receive mortality information from the Office of National Statistics for deaths occurring under the age of 65 years in the UK. The completeness of death ascertainment among UK CHIC study participants is therefore high. In CANOC, mortality ascertainment varies within participating cohorts. Two of the eight participating cohorts have established linkages to vital statistics registries, allowing for excellent ascertainment of deaths. However, other participating cohorts submit date of death as part of regular data submission to the coordinating centre, with no linkage to vital statistics, and consequently death ascertainment is less complete.

### Explanatory variables of interest {#hiv12505-sec-0012}

Explanatory variables included were age at ART initiation (per decade), sexual transmission risk category \[men who have sex with men (MSM), heterosexual male or heterosexual female\], ethnicity (Caucasian, Black, Asian, other or unknown), hepatitis C serostatus, defined as hepatitis C antibody positive at treatment initiation (yes, no or unknown), baseline diagnosis of AIDS‐defining illness (ADI) (yes or no), baseline CD4 cell count (per 100 cells/μL) and HIV RNA plasma VL (log~10~ HIV‐1 RNA copies/mL), composition of initial antiretroviral regimen, and era of ART initiation (2000--2003, 2004--2007 or 2008--2012).

Loss to follow‐up {#hiv12505-sec-0013}
-----------------

Cohort studies often fail to accurately classify mortality outcomes among persons lost to follow‐up, resulting in under‐ascertainment of deaths and affecting study validity [18](#hiv12505-bib-0018){ref-type="ref"}. Mortality among persons lost to follow‐up is reported to range from 28 to 40% [19](#hiv12505-bib-0019){ref-type="ref"}, [20](#hiv12505-bib-0020){ref-type="ref"}, [21](#hiv12505-bib-0021){ref-type="ref"}, [22](#hiv12505-bib-0022){ref-type="ref"}, [23](#hiv12505-bib-0023){ref-type="ref"}, [24](#hiv12505-bib-0024){ref-type="ref"}. Other cohort collaborations have noted considerable variation in the attrition of cohort participants; the Antiretroviral Therapy Cohort Collaboration (ART‐CC) reported that loss to follow‐up varied between participating cohorts from 2 to 18% [19](#hiv12505-bib-0019){ref-type="ref"}. We defined loss to follow‐up as no clinical contact for at least 18 months, and accounted for this important variable as a competing risk in our statistical analysis. Competing risk analyses maintain participants in the analysis who are lost to follow‐up among those who are at risk of dying, rather than censoring them at the last point of clinical contact [25](#hiv12505-bib-0025){ref-type="ref"}.

### Statistical models {#hiv12505-sec-0014}

Differences in baseline sociodemographic and clinical characteristics between cohort collaborations were evaluated using chi‐square or Fisher\'s exact test for categorical variables and the Wilcoxon rank sum test for continuous variables. Crude mortality rates were calculated per 1000 person‐years (PY) by dividing total deaths by total person‐years of follow‐up.

Competing risks Cox regression [25](#hiv12505-bib-0025){ref-type="ref"} identified variables associated with mortality during study follow‐up, accounting for loss to follow‐up as a competing risk. Previous work has shown that all‐cause mortality and causes of death differ with time since ART initiation, with all‐cause mortality highest in the first year following ART initiation, largely as a result of AIDS‐related deaths [26](#hiv12505-bib-0026){ref-type="ref"}, [27](#hiv12505-bib-0027){ref-type="ref"}. We therefore compared mortality rates between the cohort collaborations within the first year since ART initiation as well as for the entire follow‐up period. Variables considered likely to have an impact on the risk of death following literature review and clinical hypothesis were *a priori* candidates for model inclusion. Due to the large proportion of missing data for ethnicity and hepatitis C antibody status, these covariates were not included in the adjusted analysis. An exploratory model selection process based on the Akaike information criterion and type III *P*‐values was used to guide final model selection. Statistical tests were considered significant at *α* = 0.05. Analyses were conducted using [sas]{.smallcaps} 9.4 software (SAS Institute, Cary, NC, USA).

### Sensitivity analysis {#hiv12505-sec-0015}

Individuals who acquired HIV through IDU represent 17% of the Canadian population living with HIV [1](#hiv12505-bib-0001){ref-type="ref"}, [17](#hiv12505-bib-0017){ref-type="ref"}. As these individuals were excluded, CANOC participants included in the main analysis did not fully represent the Canadian population living with HIV. Previous work has shown that Canadians with a history of IDU have increased all‐cause mortality rates [28](#hiv12505-bib-0028){ref-type="ref"}, [29](#hiv12505-bib-0029){ref-type="ref"}; thus, we were aware that exclusion of injecting drug users from our main analysis would underestimate the mortality rate within CANOC. To generate crude mortality estimates more accurately representing the Canadian HIV epidemic, we performed a sensitivity analysis within an analytic sample that included participants reporting IDU transmission risk from each cohort collaboration.

Results {#hiv12505-sec-0016}
=======

Of the 19 960 individuals included in the main analysis, 4137 were CANOC and 15 823 were UK CHIC study participants. CANOC participants were older \[median 39 years (interquartile range (IQR) 33, 46 years) *vs*. 36 years (IQR: 31, 43 years) for UK CHIC participants\], and were more likely to be male (86 *vs*. 73%, respectively) and to report MSM sexual transmission risk (72 *vs*. 56%, respectively) (all *P* \< 0.001) (Table [1](#hiv12505-tbl-0001){ref-type="table-wrap"}).

###### 

Comparison of sociodemographic and clinical characteristics for the Canadian Observational Cohort (CANOC) and UK Collaborative HIV Cohort (UK CHIC) study (*n* = 19 960)

  Characteristic                                             Category                  CANOC and UK CHIC *n* (%) or median (IQR)   CANOC (*n* = 4137) *n* (%) or median (IQR)   UK CHIC (*n* = 15 823) *n* (%) or median (IQR)   *P*‐value
  ---------------------------------------------------------- ------------------------- ------------------------------------------- -------------------------------------------- ------------------------------------------------ -----------
  Gender                                                     Male                      15072 (76)                                  3572 (86)                                    11500 (73)                                       \< 0.001
  Female                                                     4888 (24)                 565 (14)                                    4323 (27)                                                                                     
  Age at ART initiation (years)                              --                        37 (31,44)                                  39 (33,46)                                   36 (31,43)                                       \< 0.001
  HIV sexual transmission risk                               MSM                       11842 (59)                                  2985 (72)                                    8857 (56)                                        \< 0.001
  Heterosexual male                                          3230 (16)                 587 (14)                                    2643 (17)                                                                                     
  Heterosexual female                                        4888 (24)                 565 (14)                                    4323 (27)                                                                                     
  Ethnicity                                                  Caucasian                 9999 (50)                                   1569 (38)                                    8430 (53)                                        \< 0.001
  Black                                                      6272 (31)                 547 (13)                                    5725 (36)                                                                                     
  Asian                                                      713 (4)                   202 (5)                                     511 (3)                                                                                       
  Mixed                                                      689 (3)                   93 (2)                                      596 (4)                                                                                       
  Other                                                      846 (4)                   285 (7)                                     561 (4)                                                                                       
  Unknown                                                    1441 (7)                  1441 (35)                                   0                                                                                             
  Hepatitis C virus positive                                 No                        10578 (53)                                  748 (18)                                     9830 (62)                                        \< 0.001
  Yes                                                        546 (3)                   129 (3)                                     417 (3)                                                                                       
  Unknown                                                    8836 (44)                 3260 (79)                                   5576 (35)                                                                                     
  Baseline CD4 count (cells/μL)                              --                        220 (120,318)                               230 (120,328)                                219 (120, 314)                                   0.007
  Baseline VL (log~10~ copies/mL)                            --                        5 (4, 5)                                    5 (4, 5)                                     5 (4, 5)                                         0.06
  ADI at baseline                                            No                        17040 (85)                                  4365 (84)                                    13575 (86)                                       0.001
  Yes                                                        2920 (15)                 672 (16)                                    2248 (14)                                                                                     
  Third drug class in first regimen                          NNRTI                     12453 (62)                                  1858 (45)                                    10595 (67)                                       \< 0.001
  Single PI                                                  718 (4)                   255 (6)                                     463 (3)                                                                                       
  Boosted PI                                                 5395 (27)                 1753 (42)                                   3642 (23)                                                                                     
  NRTI                                                       303 (2)                   84 (2)                                      219 (1)                                                                                       
  Other                                                      1091 (5)                  187 (5)                                     904 (6)                                                                                       
  Third drug in first regimen                                Efavirenz                 10148 (51)                                  1478 (36)                                    8670 (55)                                        \< 0.001
  Nevirapine                                                 2136 (11)                 309 (7)                                     1827 (12)                                                                                     
  Lopinavir                                                  2284 (11)                 618 (15)                                    1666 (11)                                                                                     
  Atazanavir                                                 1997 (10)                 902 (22)                                    1095 (7)                                                                                      
  Nelfinavir                                                 346 (2)                   148 (4)                                     198 (1)                                                                                       
  Saquinavir                                                 340 (2)                   53 (1)                                      287 (2)                                                                                       
  Other                                                      1091 (14)                 629 (15)                                    2080 (13)                                                                                     
  NRTI backbone of first regimen                             Tenofovir/emtricitabine   9262 (46)                                   1762 (43)                                    7500 (47)                                        \< 0.001
  Zidovudine/lamivudine                                      4550 (23)                 938 (23)                                    3612 (23)                                                                                     
  Tenofovir/lamivudine                                       793 (4)                   257 (6)                                     536 (3)                                                                                       
  Abacavir/lamivudine                                        2719 (14)                 677 (16)                                    2042 (13)                                                                                     
  Stavudine/lamivudine                                       579 (3)                   291 (7)                                     288 (2)                                                                                       
  Other                                                      2057 (10)                 212 (5)                                     1845 (12)                                                                                     
  Era ART initiated                                          2000--2003                4827 (24)                                   1021 (25)                                    3806 (24)                                        0.003
  2004--2007                                                 6540 (33)                 1266 (31)                                   5274 (33)                                                                                     
  2008--2012                                                 8593 (43)                 1850 (45)                                   6743 (43)                                                                                     
  Lost to follow‐up[a](#hiv12505-note-0004){ref-type="fn"}   Yes                       2548 (13)                                   556 (13)                                     1992 (13)                                        0.1
  No                                                         17412 (87)                3581 (87)                                   13831 (87)                                                                                    
  Died during follow‐up                                      Yes                       762 (4)                                     179 (4)                                      583 (4)                                          0.06
  No                                                         19198 (96)                3958 (96)                                   15240 (96)                                                                                    
  Total years of follow‐up                                   --                        4 (2, 8)                                    4 (2, 8)                                     4 (2, 8)                                         0.30

ADI, AIDS‐defining illness; VL, viral load; ART, antiretroviral therapy; IQR, interquartile range; MSM, men who have sex with men; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.

Column totals may not consistently add up to 100% because of rounding.

Loss to follow‐up is defined as no clinical contact for ≥ 18 months.

John Wiley & Sons, Ltd

###### 

Competing risk Cox regression of time to death (a) during entire follow‐up period, and (b) in the year after antiretroviral therapy (ART) initiation, with loss to follow‐up as a competing risk (*n* = 19 960)

                                          Unadjusted HR (95% CI)   Adjusted HR (95% CI)
  --------------------------------------- ------------------------ ----------------------
  \(a\)                                                            
  Cohort Collaboration                                             
  UK CHIC                                 1.00                     1.00
  CANOC                                   1.15 (0.98, 1.36)        0.86 (0.72, 1.03)
  Age at ART initiation (per decade)      1.69 (1.59, 1.80)        1.67 (1.56, 1.78)
  Sexual transmission risk                                         
  MSM                                     1.00                     1.00
  Heterosexual male                       1.50 (1.26, 1.79)        1.15 (0.96, 1.39)
  Heterosexual female                     0.88 (0.73, 1.10)        0.97 (0.80, 1.18)
  Baseline CD4 count (per 100 cells/μL)   0.78 (0.73, 0.84)        0.84 (0.78, 0.91)
  Baseline VL (log~10~ copies/mL)         1.53 (1.28, 1.84)        1.17 (0.97, 1.42)
  Third drug in first ART regimen                                  
  Efavirenz                               1.00                     1.00
  Lopinavir                               1.36 (1.10, 1.69)        1.36 (1.09, 1.69)
  Nevirapine                              1.08 (0.87, 1.34)        1.13 (0.90, 1.42)
  Atazanavir                              1.08 (0.81, 1.44)        1.22 (0.89, 1.66)
  Other                                   1.46 (1.21, 1.76)        1.45 (1.18, 1.77)
  Backbone of first ART regimen                                    
  Tenofovir/emtricitabine                 1.00                     1.00
  Zidovudine/lamivudine                   1.43 (1.17, 1.75)        1.36 (1.03, 1.81)
  Abacavir/lamivudine                     1.48 (1.15, 1.90)        1.43 (1.08, 1.90)
  Other                                   2.04 (1.67, 2.49)        1.64 (1.24, 2.16)
  Era of ART initiation                                            
  2000--2003                              1.00                     1.00
  2004--2007                              0.78 (0.66, 0.91)        0.88 (0.72, 1.07)
  2008--2012                              0.57 (0.46, 0.70)        0.84 (0.62, 1.15)
  \(b\)                                                            
  Cohort Collaboration                                             
  UK CHIC                                 1.00                     1.00
  CANOC                                   0.97 (0.7, 1.35)         0.71 (0.50, 1.01)
  Age at ART initiation (per decade)      1.62 (1.44, 1.82)        1.51 (1.34, 1.71)
  Sexual transmission risk                                         
  MSM                                     1.00                     1.00
  Heterosexual male                       2.08 (1.53, 2.83)        1.35 (0.97, 1.86)
  Heterosexual female                     0.96 (0.68, 1.36)        0.85 (0.59, 1.22)
  Baseline CD4 count (per 100 cells/μL)   0.61 (0.54, 0.69)        0.65 (0.57, 0.74)
  Baseline VL (log~10~ copies/mL)         1.53 (1.13, 2.06)        1.04 (0.78, 1.39)
  Third drug in first ART regimen                                  
  Efavirenz                               1.00                     1.00
  Lopinavir                               1.83 (1.24, 2.69)        1.81 (1.22, 2.7)
  Nevirapine                              0.68 (0.38, 1.22)        0.73 (0.4, 1.32)
  Atazanavir                              1.36 (0.84, 2.19)        1.5 (0.9, 2.49)
  Other                                   2.45 (1.78, 3.39)        2.66 (1.89, 3.73)
  Backbone of first ART regimen                                    
  Tenofovir and emtricitabine             1.00                     1.00
  Zidovudine and lamivudine               1.08 (0.75, 1.56)        1.37 (0.85, 2.21)
  Abacavir and lamivudine                 1.61 (1.09, 2.38)        1.72 (1.13, 2.63)
  Other                                   1.8 (1.28, 2.53)         1.55 (0.99, 2.41)
  Era of ART initiation                                            
  2000--2003                              1.00                     1.00
  2004--2007                              1.02 (0.74, 1.42)        1.17 (0.79, 1.72)
  2008--2012                              0.83 (0.59, 1.17)        1.32 (0.82, 2.14)

ADI, AIDS‐defining illness; CI, confidence interval; HR, hazard ratio; VL, viral load; MSM, men who have sex with men; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; CANOC, Canadian Observational Cohort; UK CHIC, UK Collaborative HIV Cohort.
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Clinical profile {#hiv12505-sec-0017}
----------------

Median baseline CD4 cell count was low across both the CANOC collaboration and UK CHIC study \[230 (IQR: 120, 328) and 219 (IQR: 120, 314) cells/μL, respectively; *P* = 0.007\] (Table [1](#hiv12505-tbl-0001){ref-type="table-wrap"}). When evaluated across the three eras of ART initiation (2000--2003, 2004--2007 and 2008--2012), median baseline CD4 count was found to increase with more recent ART era within the CANOC collaboration \[174 (IQR: 80, 263), 193 (IQR: 107, 270) and 270 (IQR: 170, 357) cells/μL, respectively\] and the UK CHIC study \[170 (IQR: 70, 271), 198 (IQR: 109, 266) and 288 (IQR: 180, 390) cells/μL, respectively\] (both *P* \< 0.001).

Treatment profile {#hiv12505-sec-0018}
-----------------

Initial ART regimen varied significantly between the cohort collaborations. A larger proportion of UK CHIC participants initiated a nonnucleoside reverse transcriptase inhibitor (NNRTI) as the third drug class within the initial regimen compared with CANOC participants (67 *vs*. 45%, respectively). CANOC participants were significantly more likely to initiate a regimen including a boosted protease inhibitor (PI) (42 *vs*. 23% in UK CHIC) (*P* \< 0.001). For both CANOC and UK CHIC participants, efavirenz was most commonly used as the third antiretroviral agent in the primary regimen (36 *vs*. 55%, respectively); however, CANOC participants were more likely than UK CHIC participants to be prescribed atazanavir (22 *vs*. 7%, respectively) (*P* \< 0.001). Era of ART initiation differed slightly between cohort collaborations, with a greater proportion of UK CHIC participants initiating ART in the era 2004--2007 compared with CANOC participants (33 *vs*. 31%, respectively; *P* = 0.003) (Table [1](#hiv12505-tbl-0001){ref-type="table-wrap"}).

Loss to follow‐up {#hiv12505-sec-0019}
-----------------

In total, 2548 participants were lost to follow‐up over a period of 98 798 PY, to give an attrition rate of 25.8 \[95% confidence interval (CI) 24.8, 26.8\] per 1000 PY. When stratified by cohort collaboration, the attrition rates were 26.9 (95% CI: 24.7, 29.2) and 25.5 (95% CI: 24.4, 26.7) per 1000 PY for CANOC and the UK CHIC study, respectively.

Mortality during total follow‐up period {#hiv12505-sec-0020}
---------------------------------------

There were 762 deaths during a total follow‐up time of 98 798 PY, giving a crude mortality rate of 7.7 (95% CI: 7.1, 8.3) per 1000 PY. When stratified by cohort collaboration, the mortality rate was 8.6 (95% CI: 7.4, 10.0) per 1000 PY among CANOC participants, and 7.5 (95% CI: 6.9, 8.1) per 1000 PY among UK CHIC participants (Figure [1](#hiv12505-fig-0001){ref-type="fig"}). In the competing risk survival analysis, no statistically significant difference in mortality was observed between the cohort collaborations after adjusting for participant age, era of ART initiation, sexual transmission risk category, CD4 cell count and VL at treatment initiation, and initial ART regimen \[adjusted hazard ratio (AHR) 0.86; 95% CI: 0.72, 1.03\] (Table [2](#hiv12505-tbl-0002){ref-type="table-wrap"}a). Notably, the direction of the cohort effect on mortality was seen to reverse in the adjusted analysis, which was largely attributed to adjustment for participant age.

![Kaplan−Meier plot showing time to death stratified by cohort collaboration (*n* = 19 960). ART, antiretroviral therapy; CANOC, Canadian Observational Cohort; UK CHIC,UK Collaborative HIV Cohort.](HIV-18-655-g001){#hiv12505-fig-0001}

Mortality in the year after ART initiation {#hiv12505-sec-0021}
------------------------------------------

There were 220 deaths during the first year after ART initiation, giving a crude mortality rate of 2.2 (95% CI: 1.9, 2.5) per 1000 PY. When stratified by cohort collaboration, the mortality rate within the first year after ART initiation was 2.2 (95% CI: 1.6, 2.9) per 1000 PY among CANOC participants, and 2.2 (95% CI: 1.9, 2.6) per 1000 PY among UK CHIC participants. In competing risk survival analysis there was no statistically significant difference in mortality in the year after ART initiation between CANOC and UK CHIC participants after adjusting for confounders (AHR 0.71; 95% CI: 0.50, 1.01) (Table [2](#hiv12505-tbl-0002){ref-type="table-wrap"}b).

Sensitivity analysis {#hiv12505-sec-0022}
--------------------

When we included participants with IDU transmission risk, 2282 participants were added to the original analytic sample: 1934 additional CANOC participants and 348 additional UK CHIC participants (see Supporting Information Tables). There were 1161 deaths during a total follow‐up time of 110 414 PY, producing a crude mortality rate of 10.5 (95% CI: 9.9, 11.1) per 1000 PY. When stratified by cohort collaboration, the mortality rate was 17.0 (95% CI: 15.6, 18.6) per 1000 PY among CANOC participants, and 8.0 (95% CI: 7.4, 8.7) per 1000 PY among UK CHIC participants. In a competing risk survival analysis, no significant difference in mortality was observed between the cohort collaborations (AHR 0.9; 95% CI: 0.8, 1.1) after adjusting for confounders (see Supporting Information Tables).

Discussion {#hiv12505-sec-0023}
==========

This analysis presents a novel comparison of sociodemographic and clinical profiles and mortality outcomes for individuals living with HIV and accessing ART within two high‐income settings: Canada and the UK. Despite differences in national HIV care provision, treatment guidelines, and clinical characteristics, mortality risk did not differ significantly between CANOC and UK CHIC study participants in Cox regression accounting for loss to follow‐up as a competing risk.

Baseline clinical profile {#hiv12505-sec-0024}
-------------------------

No clinically relevant differences in baseline CD4 cell count, VL and ADI prevalence were observed between CANOC and UK CHIC study participants within our main analysis. We hypothesized that differences were probably minimized by limiting our analysis to participants acquiring HIV through sexual transmission. However, the baseline clinical profile across cohort collaborations remained largely unchanged when participants reporting HIV acquisition through IDU were included within a sensitivity analysis. Within both cohort collaborations, CD4 cell count at treatment initiation, an important indicator of timing of treatment initiation, increased significantly with more recent treatment initiation era, reflecting evolving treatment guidelines over the period of analysis [2](#hiv12505-bib-0002){ref-type="ref"}, [30](#hiv12505-bib-0030){ref-type="ref"}, [31](#hiv12505-bib-0031){ref-type="ref"}, [32](#hiv12505-bib-0032){ref-type="ref"}.

Treatment profile {#hiv12505-sec-0025}
-----------------

Initial ART regimens differed between CANOC and UK CHIC participants, with CANOC participants being more likely to initiate boosted PI‐based regimens compared with UK CHIC participants. Both the 'third' drug in the initial treatment regimen and the backbone regimen also varied between cohort collaborations. While current treatment guidelines followed in UK and Canadian settings are broadly consistent, recommending two nucleoside reverse transcriptase inhibitors (NRTIs) plus an NNRTI or boosted PI as the initial third agent, the specific antiretroviral recommendations vary [2](#hiv12505-bib-0002){ref-type="ref"}, [7](#hiv12505-bib-0007){ref-type="ref"}, [8](#hiv12505-bib-0008){ref-type="ref"}. As well as being influenced by treatment guidelines, prescribing patterns may be based on the availability of regimens and drug costs across different settings, as well as patient and provider preferences.

The variation in treatment regimens observed in this analysis may also reflect earlier treatment guidelines within respective cohort collaboration settings. A slightly higher proportion of UK CHIC participants initiated ART between 2004 and 2007 compared with CANOC participants. Treatment guidelines published by BHIVA in 2003 [33](#hiv12505-bib-0033){ref-type="ref"} and 2005 [34](#hiv12505-bib-0034){ref-type="ref"} recommended NNRTIs over boosted PIs as the third ART agent, which could account for the comparatively low use of boosted PIs within UK CHIC overall. In contrast, the US Department of Health and Human Services (DHHS) treatment guidelines from 2003 and 2005 recommended both NNRTI‐based regimens and PI‐based regimens as equally acceptable initial ART regimens [35](#hiv12505-bib-0035){ref-type="ref"}, [36](#hiv12505-bib-0036){ref-type="ref"}.

Mortality {#hiv12505-sec-0026}
---------

According to World Health Organization (WHO) data from 2013, the adult all‐cause mortality rate among those aged 15 to 60 years in Canada is lower than in the UK (0.66 *vs*. 0.72 per 100 000 people, respectively) [37](#hiv12505-bib-0037){ref-type="ref"}. However, 2011 reports suggest that Canada has a higher HIV/AIDS‐specific mortality rate (1.1 *vs*. 0.8 per 100 000 people, respectively) [38](#hiv12505-bib-0038){ref-type="ref"}. Our analysis found that all‐cause mortality rates among CANOC and UK CHIC study participants were not significantly different both within the first year following ART initiation and during the entire follow‐up period, after adjusting for confounding variables and accounting for loss to follow‐up as a competing risk.

Limited studies have explored differences in all‐cause mortality rates among individuals living with HIV in Canada and the UK. A recent publication evaluated between‐cohort heterogeneity among participating cohorts within the ART‐CC, and reported a higher all‐cause mortality rate within the North American cohorts compared with European cohorts, even after accounting for perceived completeness of ascertainment of mortality, loss to follow‐up and baseline sociodemographic and clinical characteristics [19](#hiv12505-bib-0019){ref-type="ref"}. This finding was attributed to the higher proportion of socially marginalized individuals within North American study cohorts, who were incorrectly adjusted for in the analysis as a consequence of missing transmission risk data [19](#hiv12505-bib-0019){ref-type="ref"}. We attempted to adjust for the higher proportion of socially marginalized participants in the CANOC collaboration by limiting inclusion to participants reporting sexual transmission risk. However, we were unable to control for participant ethnicity, a key marker of socioeconomic variation and access to care within both collaboration settings, due to the large proportion of missing data within the CANOC data set.

In line with our findings, previous work has suggested that differences in sociodemographic and clinical characteristics and health service provision between HIV‐positive cohorts may have less impact on mortality following initiation of modern ART regimens. A collaborative cohort study comparing mortality rates between PLWH in high‐ and low‐income settings observed that, despite baseline differences in sociodemographic, clinical and HIV health service factors, participants demonstrated similar treatment outcomes and mortality rates in the two settings after ART initiation [39](#hiv12505-bib-0039){ref-type="ref"}.

Additional factors significantly associated with increased all‐cause mortality risk in our analysis included older age at ART initiation and lower CD4 cell count at ART initiation. These findings are consistent with previous mortality analyses within international cohort collaborations [39](#hiv12505-bib-0039){ref-type="ref"}, [40](#hiv12505-bib-0040){ref-type="ref"}, [41](#hiv12505-bib-0041){ref-type="ref"}, [42](#hiv12505-bib-0042){ref-type="ref"}, and support the consensus that ART should be initiated early in the clinical disease course to optimize clinical outcomes [43](#hiv12505-bib-0043){ref-type="ref"}, [44](#hiv12505-bib-0044){ref-type="ref"}. While there appeared to be a nominal decrease in mortality with advancing era of ART initiation in both the CANOC and UK CHIC studies, era of ART initiation did not significantly affect all‐cause mortality in the adjusted competing risks survival analysis. Previous studies in North American [41](#hiv12505-bib-0041){ref-type="ref"}, European [45](#hiv12505-bib-0045){ref-type="ref"} and multinational Euro‐North American settings [40](#hiv12505-bib-0040){ref-type="ref"} have reported decreased mortality in modern calendar periods. Our findings may signify that changes in mortality risk by era are attributed to the introduction of modern antiretroviral regimens.

Limitations {#hiv12505-sec-0027}
-----------

Readers should be aware of several limitations of our analysis. We excluded participants who acquired HIV through IDU from the main analysis to improve cohort comparability. However, MSM who reported IDU as a secondary transmission risk category could not be identified within the UK CHIC study and were coded as MSM, thus were not excluded from the main analysis. Due to the low prevalence of IDU among PLWH in the UK CHIC study, the misclassification is unlikely to have caused a considerable bias in our findings.

Completeness of death ascertainment varied across participating cohorts, with the majority of UK CHIC study mortality data supported by linkages to national vital statistics databases, and weaker vital statistics linkage capabilities overall within the CANOC collaboration. We hypothesize that the weaker ascertainment of death in the CANOC collaboration may contribute to the numerically lower mortality rates seen among CANOC participants in the multivariable analyses. A final limitation was the lack of cause‐specific mortality data within this analysis. As cause‐specific mortality data were not consistently collected across all cohorts, we were unable to differentiate between all‐cause and HIV‐specific mortality in this analysis.

Conclusions {#hiv12505-sec-0028}
===========

Among participants enrolled in two longitudinal, multi‐site clinical HIV‐positive cohorts in Canada and the UK who acquired HIV though sexual transmission routes, we observed no statistically significant difference in all‐cause mortality between cohort collaborations, despite varying approaches to clinical care and characteristics of PLWH across the two study settings.
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